{
    "nct_id": "NCT03518034",
    "official_title": "Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study",
    "inclusion_criteria": "* Men between 45 and 80 years age\n* Participants with low serum testosterone concentrations (< 300 ng/dL) who exhibit at least one sign or symptom of hypogonadism and have evidence of cardiovascular (CV) disease or are at an increased risk for CV disease.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 45 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Participants with congenital or acquired hypogonadism for whom long-term therapy with placebo would not be medically appropriate\n* Participants with prostate specific antigen (PSA) > 3.0 ng/mL (or 1.5 if on 5-alpha reductase inhibitors)\n* Participants who have been treated with testosterone in the past 6 months and for whom testosterone therapy is contraindicated\n* Confirmed testosterone < 100 ng/dL\n* Body Mass Index (BMI) > 50\n* Hemoglobin A1c (HbA1C) > 11%\n* Hematocrit (Hct) > 50%\n* Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min\n* History of deep vein thrombosis or pulmonary embolism or prostate cancer or heart failure (Class III and IV).",
    "miscellaneous_criteria": ""
}